Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Traumatic Brain Injury
Interventions
Huperzine A, Placebo
Drug
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Stroke, Acute, TBI, Neuromuscular Diseases, Status Epilepticus, Coma, Cerebrovascular Disorders, Spinal Cord Injuries, Neurological Injury, Neurologic Injury
Interventions
Timing of placement
Other
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced May 21, 2026, 6:23 PM EDT
Conditions
CDKL5 Deficiency Disorder
Interventions
ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
2 Years to 21 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Neonatal Seizures
Interventions
levetiracetam
Drug
Lead sponsor
Stephanie Merhar, MD
Other
Eligibility
Up to 30 Days
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
Enzalutamide
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
Male only
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Anchorage, Alaska • Detroit, Michigan • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Epilepsy, Tonic-Clonic
Interventions
lamotrigine (LAMICTAL) extended-release, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
64
States / cities
Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
Interventions
MagPro TMS Stimulator and coil, Thymatron(R) System IV, Magnetic Resonance Imaging Scanner, ECT device without stimulation
Device · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
25 Years to 64 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced May 21, 2026, 6:23 PM EDT
Conditions
LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)
Interventions
Not listed
Lead sponsor
Cure CMD
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Pedro, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced May 21, 2026, 6:23 PM EDT
Terminated Phase 4 Interventional Results available
Conditions
Intracranial Aneurysms, Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (bumetanide analog) or Matching Placebo
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Epilepsy
Interventions
YKP3089, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced May 21, 2026, 6:23 PM EDT
Not listed No phase listed Observational
Conditions
Epilepsy
Interventions
Non-interventional
Other
Lead sponsor
Neuroendocrine Associates P.C.
Other
Eligibility
18 Years to 47 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Wellesley, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Seizures, Disorder of Fetus or Newborn
Interventions
Low dose levetiracetam, High dose levetiracetam
Drug
Lead sponsor
Richard H. Haas
Other
Eligibility
1 Minute to 14 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Epilepsy (Treatment Refractory)
Interventions
Seizure risk forecast, Control seizure risk forecast
Other
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced May 21, 2026, 6:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Pregnancy, Preeclampsia
Interventions
abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery)
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced May 21, 2026, 6:23 PM EDT
Withdrawn Not applicable Interventional
Conditions
Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, Focal Seizures
Interventions
Turmeric
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Epilepsy
Interventions
GW273225
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
30
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Subarachnoid Hemorrhage
Interventions
Brief LEV, Extended LEV
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced May 21, 2026, 6:23 PM EDT
Recruiting Not applicable Interventional
Conditions
Epilepsy, Brain Tumor
Interventions
Language-based tasks
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced May 21, 2026, 6:23 PM EDT
Conditions
Transformed Migraine, Chronic Daily Headache
Interventions
SPG Block with 5% Lidocaine gel, Amitriptyline
Procedure · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced May 21, 2026, 6:23 PM EDT